Finance

Lists
Outlook: 0.0% bullish·100.0% bearish
Go to analysis
CRBU:NASDAQ
Caribou Biosciences Inc
$1.14
0.00%
(0.00) 1D
$0.64
-44.05% (-0.50)
Pre-market
Closed: Oct 6, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBU...
Mkt. cap
124.75M
Avg. vol.
1.28M
Volume
2.31M
52-wk high
$3.53
52-wk low
$1.13
EPS
-$1.08
Beta
2.31
Shares outstanding
107.21M
No. of employees
97
Mkt. cap
124.75M
Avg. vol.
1.28M
Volume
2.31M
52-wk high
$3.53
52-wk low
$1.13
EPS
-$1.08
Beta
2.31
Shares outstanding
107.21M
No. of employees
97
News stories
From web sources and news partners
About Caribou Biosciences Inc
CEO-
Employees97
FoundedJan 1, 2011
HeadquartersBerkeley, California, United States
SectorBiotechnology
Websitecariboubio.com
Analyst ratings
Based on 5 analysts giving stock ratings to CRBU in the past 3 months
Buy
Buy
2
Hold
3
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CRBU in the last 3 months.
Highest
Current $1.14
$8.00 (+604.85%)
Average
$3.75 (+230.40%)
Lowest
$1.00 (-11.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daina Graybosch
Leerink Partners
Hold
Downgraded
$1.00
-11.9%
10/06/2026
Luca Issi
RBC Capital
Hold
Downgraded
$1.00
-11.9%
10/06/2026
Leah R. Cann
Brookline Capital Markets
Hold
Downgraded
-
-
10/06/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
$5.00
+340.5%
08/14/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$8.00
+604.8%
08/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$11.00
+869.2%
06/16/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$13.00
+1,045.4%
03/09/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
$7.00
+516.7%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$4.00
+252.4%
03/06/2026
William Maughan
Clear Street
Buy
Maintained
$13.00
+1,045.4%
03/06/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.24 / -$0.31
+21.74%beat
Revenue / Est. (USD)
1.50M / 2.25M
-33.25%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.20M
3.94M
2.40M
1.50M
Cost of goods sold
22.40M
23.82M
20.61M
18.94M
Cost of revenue
22.40M
23.82M
20.61M
18.94M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.20M
8.58M
8.07M
7.90M
Operating expense
9.20M
8.58M
8.07M
7.90M
Total operating expenses
31.60M
32.39M
28.68M
26.84M
Operating income
-29.40M
-28.45M
-26.28M
-25.34M
Other non operating income
-
42.00K
-
-
EBT including unusual items
-27.55M
-27.04M
-25.08M
-24.28M
EBT excluding unusual items
-27.55M
-27.04M
-25.08M
-24.28M
Income tax expense
-
-550.00K
-
-
Effective tax rate
-
2.03%
-
-
Other operating expenses
-
-
-
-
Net income
-27.55M
-26.49M
-25.08M
-24.28M
Net profit margin
-1,253.32%
-672.11%
-1,046.52%
-1,619.88%
Earnings per share
-
-
-0.26
-0.24
Interest and investment income
1.85M
1.37M
1.20M
1.06M
Interest expense
-
-
-
-
Net interest expenses
1.85M
1.37M
1.20M
1.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.77M
-27.77M
-25.63M
-24.71M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps